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Notes on Hypothesis Testing under a Single-Stage Design in Phase II Trial
Kung-Jong Lui
San Diego State University,
San Diego, CA USA
A primary objective of a phase II trial is to determine future development is warranted for a new
treatment based on whether it has sufficient activity against a specified type of tumor. Limitations exist in
the commonly-used hypothesis setting and the standard test procedure for a phase II trial. This study
reformats the hypothesis setting to mirror the clinical decision process in practice. Under the proposed
hypothesis setting, the critical points and the minimum required sample size for a desired power of
finding a superior treatment at a given α -level are presented. An example is provided to illustrate how
the power of finding a superior treatment by accounting for a secondary endpoint may be improved
without inflating the given Type I error.
Key words: Phase II trial, Type I error, power, union-intersection test, sample size, equivalence.
Despite employing a large sample size
to meet a desired power, the probability of
excluding a potentially interesting treatment
from further consideration can still be large. To
illustrate the above points, for example, consider
testing H 0 : p ≤ 0.30 versus H a : p ≥ 0.50 at
the 0.05 level. When using the common sample
size calculation formula for a desired 90%
power of rejecting H 0 : p ≤ 0.30 for p = 0.50 at
the 0.05-level, the minimum required sample
size is determined to be 49 patients.
Suppose that ( x = ) 20 patients respond
among these ( n = ) 49 patients (i.e., the sample
proportion response p = 20/49 = 0.408). Using

Introduction
One of the primary objectives in a phase II trial
for a new anti-cancer treatment is to make a
preliminary determination on whether the
treatment has sufficient activity or benefits
against a specified type of tumor to warrant its
further development. Based on subjective
knowledge, researchers commonly choose two
response rates in advance p0 and p1 (where

0 < p0 < p1 < 1 ) for the uninteresting and
desirable levels, respectively. Test hypotheses:
H 0 : p ≤ p0 versus H a : p ≥ p1 (Simon, 1989;
Lin, Allred & Andrews, 2008; Lu, Jin &
Lamborn, 2005) are considered using p1 to
determine the minimum required sample size for
a desired power 1 − β of rejecting H 0 : p ≤ p0

these data, the p-value for testing H 0 : p ≤ 0.30
is 0.049 (on the basis of normal approximation)
and thereby, H 0 is rejected at the 0.05 level.

at a nominal α -level when p = p1 . This
hypothesis setting can cause clinicians to
misinterpret their findings that rejecting the null
hypothesis H 0 : p ≤ p0 is equivalent to
supporting
the
alternative
hypothesis
H a : p ≥ p1 and vice versa (Storer, 1992).

Note that because p = 20/49 (= 0.41) is less
than 0.50, there is no evidence that the
underlying response rate p is larger than 0.50.
Conversely, there is statistically significant
evidence, given p = 20/49, to indicate that the
underlying response rate p is less than the
desirable level 0.50 at the 10% level for testing
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H 0 : p ≥ 0.50
versus
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H a : p < 0.50 .
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accommodate a two-sample randomized
comparative trial. In fact, the design suggested
by Sargent, Chan & Goldberg (2001) can be
expressed in terms of Storer’s setting (1989) by
treating H 0 and H a as two competing null
hypotheses in the following:

Furthermore, when a treatment has the response
rate p = 0.35 (which is larger than the
uninteresting level p = 0.30) and is of potential
interest, it can be shown that the probability of
terminating this treatment for further
consideration by not rejecting H 0 : p ≤ 0.30 is
approximately 80%.
The above concerns and criticisms are
partially due to the fact that the complement of
{ p| p ≤ p0 } is not the set { p| p ≥ p1} and there
is no explicit instruction about what should be
done when the underlying response rate p falls

(1) testing H 0 : p ≤ p0 (versus p > p0 ) at α level, and rejecting H 0 when X ≥ ru where

ru is the minimum point satisfying
P( X ≥ru | p= p0 )≤α ;
(2) testing H a : p ≥ p1 (versus p < p1 ) at β level, and rejecting H a when X ≤ rl ,
where rl is the maximum point satisfying
P( X ≤rl | p= p0 )≤β .

in the borderline region { p| p0 < p < p1 } . This
motivates the recent development of a design
with three outcomes, including an outcome
allowable to account for other factors, including
toxicity, cost or convenience, when making a
decision (Storer, 1992; Sargent, Chan &
Goldberg, 2001; Hong & Wang, 2007). One
intuitive and logical justification of this practice
is that - if the response rate of a new treatment
was not much different from that of the standard
treatment - it would be reasonable to recommend
the new treatment for further study if the new
treatment was less toxic, cheaper and/or easier to
administer.
Treating both H 0 :{ p| p ≤ p0 } and

The
inconclusive
region
then
simply
corresponds to the set of sample points
{rl < X < ru } . Based on the normal
approximation, it can be shown that the
inconclusive region consists of
{X| np1 − Z β np1 (1− p1 ) -0.5
<X<

np0 + Zα np0 ( 1 − p0 ) + 0.5},

H a :{ p| p ≥ p1 } as two separate competing null
hypotheses, Storer (1992) proposed a threeoutcome design to accommodate the situation in
which one might reject neither H 0 nor H a and
he suggested sample size calculation based on
P( X ≥ ru | H 0 ) ≤ α , P( X ≤ rl | H a ) ≤ β , and

where Zα is the upper 100( α )th percentile of the
standard normal distribution. Note that this
inconclusive region is a function of errors α ,
β , and the sample size, which are all operating
parameters of the statistical test procedure rather
than the biological characteristics of patient
response to treatments. Various choices of α ,
β , or the sample size can lead to obtain
different inconclusive regions despite that the
underlying p1 and p0 are fixed. This is not
appealing because the inconclusive region
should represent the values falling in the
borderline between the uninteresting and
desirable levels and should be related to the
biological aspects. Furthermore, it is possible
that both H 0 : p ≤ p0 and H a : p ≥ p1 may be
rejected in the design proposed by Sargent, Chan
& Goldberg (2001); in this case, the above
inconclusive region will no longer exist. This

P( rejecting Hi | pm ) ≤ γ for i = 0, a , where
ru and rl are minimum and the maximum

critical points satisfying the above probability
constrains and where pm ≈ ( p0 + p1 ) / 2 .
On the basis of Simon’s setting (1989)
and the normal approximation for the binomial
distribution, Sargent, Chan & Goldberg (2001)
proposed a three-outcome test procedure with an
inconclusive region in which neither H 0 nor

H a were rejected and they discussed sample size

calculation for given errors of α and β , and
the minimum probabilities of concluding
correctly. Hong & Wang (2007) further
extended
sample
size
calculation
to
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disadvantage are noted and compared with the
proposed procedure.

can occur even when the sample size is
moderate and both α and β errors are
controlled.
To clarify this point, consider the above
example of testing H 0 : p ≤ 0.30 versus

Notation and Hypothesis Testing
Consider a phase II trial in which a
random sample of size n patients is taken from a
studied population and assigned to receive a new
treatment under study. Suppose that x out of n
patients are obtained with objective (or primary)
response. Let p0 denote the objective response
rate determined from the historical data for the
standard treatment. Let δ denote the level of
difference such that, if the objective response
rate p is larger than pu = p0 +δ , the new
treatment is regarded as superior to the standard
treatment and hence is warranted for further
study.
Similarly, if the objective response rate
p is less than pl = p0 −δ , the new treatment is
regarded as inferior to the standard treatment
and is terminated from further investigation.
Recall that in the standard setting, statistical
significance against H 0 : p ≤ p0 does not
provide information on how large the difference
p - p0 is between the new and standard
treatments. By contrast, statistical significance
evidence to support that p > p0 + δ (i.e., the
new treatment is larger than the standard
treatment by a magnitude δ of clinical
significance) will provide better evidence.
Conversely, when statistically significant
evidence exists that the new treatment is inferior
to the standard treatment (i.e., p < p0 − δ ), the
new treatment may be excluded from further
consideration for ethical reasons. This
occurrence will not be known unless the data
against the hypothesis p≥ p0 −δ is examined.
Thus, despite the fact that the main interest in a
phase II trial is to find a potentially promising
treatment, the critical region may also include
the sample points to test the hypothesis
p≥ p0 −δ . However, the calculation of sample
size required for power of detecting a given
p( < p0 −δ ) is of no practical interest. Defining
pl = p0 −δ and pu = p0 +δ , therefore, the
hypotheses considered in testing are:

H a : p ≥ 0.50 . Given ( x = ) 20 patients with
response

among

( n=

)

49

patients,

H 0 : p ≤ 0.30 can be rejected at α = 0.05 level
and H a : p ≥ 0.50 would be rejected at β =

0.10 level. When choosing α = 0.05 and β =
0.10, by definition ru < rl in this case and the
inconclusive region does not exist. There is no
discussion on what action to take when both
H 0 : p ≤ p0 and H a : p ≥ p1 are rejected in the
three-outcome design as proposed previously
(Storer, 1992; Sargent, et al., 2001; Hong &
Wang, 2007).
When determining in practice whether a
new treatment warrants further study at the end
of a phase II trial the decision is almost always
based on multiple risk/benefit considerations
rather than the testing result of a single primary
endpoint, especially when no clear decision can
be derived from the testing result. In other
words, unless the response rate of the new
treatment can be shown to be different from that
of the standard treatment by a magnitude of
clinical importance, relevant factors are
incorporated into the determination of whether
the new treatment should be studied further.
Thus, it is desirable to design a test procedure
that can mirror the clinical decision process in
reality.
To avoid distracting readers’ attention
from the main focus of this article, discussion is
restricted to a single-stage design. Under the
proposed setting, the critical points and the
minimum required sample size for a desired
power of finding a superior treatment in a
variety of situations are presented. Furthermore,
using an idea suggested by Lin, Allred and
Andrews (2008) and Lu, Jin and Lamborn
(2005), an example is included to illustrate how
the power of detecting a superior treatment may
be improved by considering a secondary
endpoint without inflating the given Type I
error. Finally, another alternative procedure is
considered and its difference, advantage, and
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H 0 : pl ≤ p ≤ p u
versus

Ha : p> pu or p< pl .

Φ ( n, p, α1 , α 2 , δ ) ≥ 1 − β .

Sample Size Determination and Critical Points
Programs were written in SAS (1990) to
find the minimum required sample size n
satisfying equation (5). For illustration purposes,
δ = 2.5% was arbitrarily chosen for the
following discussion. Table 1 summarizes the
critical points x u (α1 ) , x l (α 2 ) , and the
minimum required sample size n for
α1 = α 2 = 010
.
calculated
from

H 0 : pl ≤ p ≤ pu will be rejected at the α -level
if x ≥ x u (α1 ) or x ≤ x l (α 2 ) , where
α = α1 + α 2 , xu (α1 ) is the minimum point
such that

P( X ≥ xu ( α1 )| pu ) =



n
x = xu ( α1 )

n x
n− x
  pu ( 1 − pu ) ≤ α1 ,
x
 

Φ(n, p, α1 , α 2 ) ≥ 1 − β (5) for a desired power
1− β = 0.80, 0.90 in testing

(2)

H 0 : pl ≤ p ≤ p u

and x l (α 2 ) is the maximum point such that

versus

P( X ≤ xl ( α 2 )| pl ) =



xl ( α 2 )
x =0

n x
n− x
  pl ( 1 − pl ) ≤ α 2 .
 x

(5)

(1)

(3)

H a : p > pu or p < pl ,

where pl = p0 − δ , pu = p0 + δ , δ = 2.5%;
p0 = 0.15, 0.25, 0.35, 0.45, 0.55, 0.65, 0.75; and

p = p0 + 015
. , p0 + 0.20 .

Note that the hypothesis setting (1) is
simply a switch between the null and alternative
hypotheses when testing equivalence (Dunnett &
Gent, 1997; Westlake, 1979; Liu & Weng, 1995;
Liu & Chow, 1992; Hauck & Anderson, 1984;
Lui, 1997a, 1997b; Lui & Cumberland, 2001a,
2001b). Note also that the above test procedure
for (1) is a union-intersection test (Casella &
Berger, 1990). When making an error in
recommending an ineffective or harmful
treatment for phase III trial is considered more
serious than making an error of missing a
potentially interesting treatment, an investigator
may wish to choose α1 ≤ α 2 .

For example, consider testing

H 0 :0.325 ≤ p ≤ 0.375 (i.e., p0 = 0.35)
versus

H a : p > 0.375 or p < 0.325

. . If the desired
at levels of α1 = α 2 = 010
power for rejecting H 0 when the underlying
objective response rate p equals 0.50 is 80%, for
example, based on equation (5), 77 patients
would be required. Furthermore, Table 1 shows
that if ( xu ( α1 )) = 35 or more patients are

For a given true value p ∈{p| p > pu } ,
the power is equal to

obtained with an objective response out of the
77 patients, then the new treatment would be
recommended for further study.
On the other hand, if 19 or less patients
are obtained with objective responses, the new
treatment would be terminated from further
consideration. Finally, if the number of patients
with objective responses falls between 20 and
34, other factors would be considered to
determine whether the experimental treatment
warrants further study. Table 2 summarizes the
corresponding critical points x l (α 2 ) , x u (α1 )

Φ ( n, p,α1 ,α 2 ,δ ) =
P( X ≤ xl ( α 2 )| p ) + P( X ≥ xu ( α1 )| p ).
(4)
Thus, given p, α1 , α 2 , and δ , a trial-and-error
procedure can be applied to determine the
critical points: x l (α 2 ) and x u (α1 ) , as well as
the minimum required sample size n for a
desired power 1 − β based on (4) such that
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Table 1: The critical points x l (α 2 ) , x u (α1 ) and
the minimum required sample size n calculated
from Φ(n, p, α1 , α 2 ) ≥ 1 − β in equation (5) for

and the minimum required sample size n for α1

= 0.05 and α 2 =0.15 in the same configurations
as those considered in Table 1.

a desired power 1− β = 0.80, 0.90 in testing

Discussion
Multiple factors are almost always accounted for
at the end of a phase II trial to determine
whether a new treatment warrants further study
unless there is a clear cut decision in the testing
results. The test procedure proposed herein has
the advantage of resembling the actual clinical
decision process more closely than the standard
test procedure. By contrast, in Simon’s setting,
the determination of a new treatment for further
study may completely depend on the testing
result of a single primary point, but this may not
be the case in practice. Furthermore, in the
three-outcome design, the inconclusive region
depends on the operating characteristics, such as
errors α , β , and the sample size, of a test
procedure. Thus, the inconclusive region can
change or may not even exist for different given
values of these parameters even when the
underlying objective response rate is fixed. For
this reason the inconclusive region is defined
here in terms of biological equivalence. Based
on the proposed hypothesis setting (1), it is
possible to control both the errors of
recommending a non-superior treatment and of
terminating a non-inferior treatment to be less
than a given error-level.
When there is no statistical evidence
against the hypothesis H 0 : p ∈[ pl , pu ] based
on the primary endpoint, a reasonable and
appealing action can be to consider a secondary
endpoint to improve power. For example, in
traditional phase II trials, the total response (TR)
rate, the sum of the complete response (CR) rate
and the partial response (PR) rate, is often used
as the objective (or primary) response rate p.
Because CR is generally rare for many tumors,
even a small increase in the number of CRs can
be important in evaluation of the efficacy of a
treatment. Thus, clinicians will welcome a
decision rule that accepts a new treatment for
further study based on an improved CR rate
even when the treatment does not achieve the
desirable objective response rate of TR (Lin,
Allred & Andrews, 2008; Lu, Jin & Lamborn,
2005).

H 0 : pl ≤ p ≤ pu versus H a : p > pu or p < pl
where pl = p0 − δ , pu = p0 + δ , δ = 2.5%;
p0 = 0.15, 0.25, 0.35, 0.45, 0.55, 0.65, 0.75;
. , p0 + 0.20 ; α1 = 0.10 and α 2 =
p = p0 + 015
0.10.

p0

p

n

xl (α 2 )

xu (α1 )

1− β = 0.80
0.15
0.25
0.35
0.45
0.55
0.65
0.75

0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95

51
31
68
36
77
41
77
37
73
36
59
30
39
16

2
1
10
4
19
9
26
11
32
14
31
14
24
8

13
9
24
14
35
20
43
22
48
25
45
24
34
15

1− β = 0.90
0.15
0.25
0.35
0.45
0.55
0.65
0.75
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0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95

79
45
94
52
109
53
105
54
101
50
83
41
61
22

5
2
15
7
28
12
37
17
46
21
45
21
39
12

19
12
32
19
48
25
57
31
65
34
62
32
52
20
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Table 2: The critical points x l (α 2 ) , x u (α1 ) and
the minimum required sample size n calculated
from Φ(n, p, α1 , α 2 ) ≥ 1 − β in equation (5) for a

When studying the efficacy of a
treatment for brain tumors the TR rate can be
small as well. In this case, the objective response
can be stabilization disease (SD) progression for
six months after post-treatment initiation, while
the secondary endpoint can be either CR or PR.
For both of the above examples, a critical region
may be found based on the objective and
secondary responses such that if the objective
response rate cannot be used to decide whether a
new treatment warrants further study, an
opportunity may still exist to justify the
acceptance of the new treatment based on its
secondary response rate subject to the originally
given α1 error. To illustrate this point, consider
the example for patients with glioblastomas. On
the basis of the standard for the North American
Brain Tumor Consortium (NABTC), interest lies
in determining whether the objective response
rate of SD increases from p0 = 0.15 to p= 0.35
(Lu, Jin & Lamborn, 2005). Thus, testing

desired power 1− β = 0.80, 0.90 in testing

H 0 : pl ≤ p ≤ pu versus H a : p > pu or p < pl ,
where pl = p0 − δ , pu = p0 + δ , δ = 2.5%;
p0 = 0.15, 0.25, 0.35, 0.45, 0.55, 0.65, 0.75; p =
p0 + 015
. , p0 + 0.20 ; α1 = 0.05 and α 2 =0.15.
p0

p

n

xl (α 2 )

xu (α1 )

1− β = 0.80
0.15
0.25
0.35
0.45
0.55
0.65
0.75

0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95

73
41
92
48
102
50
103
53
95
48
81
41
56
26

5
2
16
7
27
12
38
18
44
21
45
21
36
15

19
12
33
19
47
25
58
32
63
34
62
33
49
24

H 0 :0125
.
≤ p ≤ 0175
.
(with δ = 2.5%)
versus

is considered. From equation (5), the minimum
required number of patients is determined to be
31 patients for a desired power of 80% when p =
0.35 at ( α1 = α 2 = ) 0.10-level and the

1− β = 0.90
0.15
0.25
0.35
0.45
0.55
0.65
0.75

0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95

102
55
121
66
136
71
140
72
129
64
110
53
78
32

8
3
21
10
38
18
52
25
61
28
62
28
51
20

H a : p > 0175
.
or p < 0125
.

corresponding
25
15
42
25
61
34
77
42
84
44
83
42
67
29

critical

points

xl (α 2 ) and

xu (α1 ) are 1 and 9, respectively (Table 1).

When no evidence exists to claim the
experimental treatment to be superior (i.e.,
p > 0175
. ) to the standard treatment based on
the objective response rate of SD, for example,
the experimental treatment may be still
determined to warrant further study. This could
occur if the secondary response rate, pS , that
the tumor shrinkage is sufficient to be regarded
as either CR or PR for a 6-month interval is
larger than 0.05.
Let x s denote the number of patients
with the secondary response among 31 patients.
While keeping the above critical point x u (α1 )
for the objective response of SD, SAS programs
are written to search for the secondary endpoint
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for the critical point x CS , which is the minimum

treatment is recommended for further study if
the new treatment has either a high objective
response rate or a high secondary response rate.
Thus, Conaway & Petroni’s results cannot be
applicable to the situations discussed here.
It may be shown that

point x S such that the probability P( X ≥ 9 or

X s ≥ x S | pu = 0175
. , pS = 0.05) ≤ 010
. . The
critical point, x CS , is 5 if an observation ( x , x S )
= (8, 6) is obtained. Although the number (x = 8)
of patients with the objective response of SD is
not ≥ 9, the experimental treatment may be
recommended for further development because
the number of ( x S = 6) patients with the
secondary response is above the critical point (
x CS =5). In fact, the joint power for given values

 n
n
P( X ≥ x| p) (=  X = x  p x (1− p) n − x ) ≤α *
 X
if and only if the 100(1- α )% lower confidence
limit
(LCL)
(one-sided),
given
by
x /( x +(n− x +1) F2 ( n − x +1),2 x ,α * ) , falls above the
*

p and pS based on the trinomial distribution can
also be calculated:

underlying response rate p, where F2 ( n − x + 1),2 x ,α *

P( X ≥ 9 or X s ≥ 5 | p, pS ) =

1
i

j ( i + j ≥9 ori ≥5 }

is the upper 100( α )th percentile of the central
F-distribution with degrees of freedom
2(n− x +1) and 2x , respectively (Casella &
Berger, 1990; Lui, 2004). Similarly, it can be
*
shown that P( X ≤ x| p) ≤α if and only if the
*

31!
(6)
i! j !( n − i − j )!

× pSi ( p − pS ) j ( 1 − p )( 31−i − j )

100(1- α )% upper confidence limit (UCL)
(one-sided), given by
*

where the indicator function, 1{condition} , equals 1
if the condition in braces is true, and equals 0
otherwise.
For example, when p = 0.35 and pS =
0.20, the joint power obtained from (6) ≈ 0.88,
which is larger than the original desired actual
power P( X ≥ 9| p = 0.35) ≈ 0.81 exclusively
based on the objective response by
approximately 7%. Note that because the
binomial distribution is discrete, the true Type I
. ) based on the
error P( X ≥ 9| pu = 0175
objective response is actually equal to 0.079,
which is less than the nominal ( α1 = 0.10) level.
This is the reason why the critical region can be
expanded from { X ≥ 9} to {X ≥ 9 or X S ≥ 5}
to increase power without the necessity of
inflating the given α1 error. Conaway & Petroni
(1995) proposed methods for designing group
sequential phase II trials with two binary
endpoints.
Conaway & Petroni (1995) also focused
discussion on the situation in which a new
treatment is recommended for further study
when the new treatment has both a high
response and lower toxicity. By contrast,
consider the situation in which the new

{( x + 1 )F2( x +1 ),2( n − x ),α* }
{( n − x ) + ( x + 1 )F2( x +1 ),2( n − x ),α* }
falls below p. Thus, the hypothesis setting and
test procedure defined in (1-3) is equivalent to
the decision procedure defined as follows: when
the UCL with α * =α 2 falls below pl ( = p0 −δ ) ,
the new treatment is terminated; when the LCL
with α * =α1 falls above pu ( = p0 +δ ) , the new
treatment warrants further consideration; when
neither of the above conditions hold relevant
factors are accounted for in the final decision.
Compared with hypothesis testing, the use of
confidence intervals to present the testing results
may shed light on the magnitude of the
difference between the two treatments under
comparison.
Rather than excluding a new treatment
from further consideration when it is shown to
be inferior (i.e., p< p0 −δ ) to the standard
treatment in the procedure proposed, an
alternative procedure can be considered by
including a new treatment into further
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consideration only when it is shown to be noninferior to the latter (i.e., p> p0 −δ ). That is, the
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